We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Mechanism Described for Cytotoxicity Regulation against Influenza A

By LabMedica International staff writers
Posted on 20 Oct 2016
Print article
Image: Neutralizing antibodies that bind to specific antigens on the flu virus may aid in the development of a universal influenza vaccine (Photo courtesy of Dr. Matthew Miller, McMaster University).
Image: Neutralizing antibodies that bind to specific antigens on the flu virus may aid in the development of a universal influenza vaccine (Photo courtesy of Dr. Matthew Miller, McMaster University).
A new discovery that revealed how neutralizing antibodies bind to specific antigens on the flu virus may aid in the development of a universal influenza vaccine.

In addition to binding and neutralizing antigens, antibodies are also capable of stimulating cellular responses through Fc–Fc receptor interactions. The fragment crystallizable region (Fc region) is the tail region of an antibody that interacts with cell surface receptors called Fc receptors and some proteins of the complement system. The Fc region of all antibodies in a class is the same for each species; they are constant rather than variable.

The type of response stimulated by these interactions is influenced by both the Fc receptor type expressed on the effector cell and the isotype of antibody to which it is bound. However, how antibody specificity influences Fc receptor functions, and how antibodies of different specificities interact to modulate these functions, remain unknown.

Investigators at McMaster University (Hamilton, Canada) used influenza A virus as a model to demonstrate that antibody specificity profoundly influenced the induction of antibody-dependent cell-mediated cytotoxicity by effector cells. They reported in October 3, 2016, online edition of the journal Proceedings of the [U.S.] National Academy of Sciences that the generation of strain-specific neutralizing antibodies against influenza A virus was known to confer potent protection against homologous infections. The majority of these antibodies bound to the hemagglutinin (HA) head domain and functioned by blocking the receptor-binding site, preventing infection of host cells.

Elicitation of broadly neutralizing antibodies, which target the viruses' conserved HA stalk domain, has become a promising “universal” influenza virus vaccine strategy. The ability of these antibodies to elicit Fc-dependent effector functions has emerged as an important mechanism through which protection is achieved in vivo. However, the way in which Fc-dependent effector functions are regulated by polyclonal influenza virus-binding antibody mixtures in vivo has never been defined.

In the current study, the investigators demonstrated that interactions among viral glycoprotein-binding antibodies of varying specificities regulated the magnitude of antibody-dependent cell-mediated cytotoxicity induction. They showed that the mechanism responsible for this phenotype relied upon competition for binding to HA on the surface of infected cells and virus particles. Non-neutralizing antibodies were poor inducers and did not inhibit antibody-dependent cell-mediated cytotoxicity.

“Our findings show that just having antibodies is not enough. You have to have antibodies that bind to very specific places on the virus,” said senior author Dr. Matthew Miller, assistant professor of biochemistry and biomedical sciences at McMaster University. “Now that we know the places where antibodies have to bind, we can modify our vaccines so that we generate those antibodies in higher numbers. Using this knowledge, what we can now do is specifically design our universal vaccine to generate the most desirable types of antibodies and avoid antibodies that block the functions that we want. In doing that, we can make sure that the vaccine will work in the most effective way possible.”

Related Links:
McMaster University


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
HLX
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Real-time PCR System
GentierX3 Series

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: The study showed the blood-based cancer screening test detects 83% of people with colorectal cancer with specificity of 90% (Photo courtesy of Guardant Health)

Blood Test Shows 83% Accuracy for Detecting Colorectal Cancer

Colorectal cancer is the second biggest cause of cancer deaths among adults in the U.S., with forecasts suggesting 53,010 people might die from it in 2024. While fewer older adults are dying from this... Read more

Hematology

view channel
Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)

First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy

Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read more

Microbiology

view channel
Image: The new platform is designed to perform blood-based diagnoses of nontuberculosis mycobacteria (Photo courtesy of 123RF)

New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours

Breathing in nontuberculous mycobacteria (NTM) is a common experience for many people. These bacteria are present in water systems, soil, and dust all over the world and usually don't cause any problems.... Read more

Industry

view channel
Image: These new assays are being developed for use on the recently introduced DxI 9000 Immunoassay Analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics

Beckman Coulter Diagnostics (Brea, CA, USA) and Fujirebio Diagnostics (Tokyo, Japan) have expanded their partnership focused on the development, manufacturing and clinical adoption of neurodegenerative... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.